Sport-Specific Use of Doping Substances: Analysis of World Anti-Doping Agency Doping Control Tests between 2014 and 2017. by Aguilar Navarro, Millán et al.
1 
 
Sport-specific use of doping substances: analysis of World Anti-Doping Agency 1 
doping control tests between 2014 and 2017 2 
 3 
Running Head: Prohibited substances across Olympic sports  4 
 5 
Authors: Aguilar-Navarro M1,  Salinero Martín JJ2, Muñoz-Guerra J 3, Plata M4 and 6 
Del Coso J5.  7 
 8 
1Francisco de Vitoria University. Exercise and Sport Sciences. Faculty of Health 9 
Sciences.  Madrid, Spain. 10 
2Camilo José Cela University.  Exercise Physiology Laboratory.  Madrid, Spain. 11 
3Spanish Agency for Health Protection in Sport.  Department for Doping Control. 12 
Madrid, Spain. 13 
4Spanish Agency for Health Protection in Sport.  Department of Education.  Madrid, 14 
Spain. 15 




Background: In recent years, there has been a solid effort across all sports organisations 18 
to reduce the prevalence and incidence of doping in sport. However, the efficacy of 19 
current strategies to fight against doping might be improved by using anti-doping polices 20 
tailored to the features of doping in each sport. Objectives: The aim of this investigation 21 
was to analyse the substances more commonly found in doping control tests in individual 22 
and team sports. Material and Methods: The publicly accessible Testing Figures Reports 23 
made available by the World Anti-Doping Agency, were analysed from 2014 to 2017. 24 
Results: The most commonly detected groups of banned substances were anabolic agents 25 
and stimulants but the distribution of adverse findings per drug class was very different 26 
depending on the sports discipline. Weightlifting, athletics, rugby, hockey and volleyball 27 
presented abnormally high proportions of anabolic agents (p=2.8×10-11).  Cycling, 28 
athletics and rugby presented atypically elevated proportions of peptide hormones and 29 
growth factors (p=1.4x10-1). Diuretics and masking agents were more commonly found 30 
in boxing, wrestling, taekwondo, judo, shooting, and gymnastics than in other sports 31 
(p=4.0×10-68). Cycling, rowing, aquatics, tennis, gymnastics and ice hockey presented 32 
abnormally high proportions of stimulants (p=1.8.x10-5). Conclusions:  These results 33 
indicate that the groups of banned substances more commonly detected in anti-doping 34 
control tests were different depending on the sports discipline. These data suggest the 35 
prohibited substances used as doping agents might be substantially different depending 36 
on the type of sport and thus, sports-specific anti-doping policies should be implemented 37 
to enhance the efficacy of anti-doping testing. 38 
 39 
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 Doping in sport is a well-studied phenomenon from both medical and 43 
psychosocial perspectives (Pielke, 2018), and one of the most recurrent conclusions is 44 
that doping might vary greatly depending on the type of sport, sports level, and athletes’ 45 
attitudes and beliefs, with other contributors from the context surrounding the athlete that 46 
also affects doping misconduct (Morente-Sánchez & Zabala, 2013).  However, current 47 
knowledge about doping practices has not always been effectively translated to the fight 48 
against doping.   49 
After years of apparent disorganisation in the fight against doping, the World 50 
Anti-Doping Agency (WADA) was conceived to harmonise anti-doping policies 51 
worldwide and to equilibrate the pressure of the fight against doping among sports.  In 52 
this respect, one of the most important achievements against doping has been the 53 
implementation of a homogeneous set of anti-doping rules, such as the World Anti-54 
Doping Code (World Anti-Doping Agency, 2015).  The Code has provided the 55 
framework for coordinated policies, rules and regulations among sports organisations and 56 
public authorities (Lippi, Franchini, & Guidi, 2008).  The Code has also allowed the 57 
publication of an annually updated Prohibited List of Substances and Methods that is the 58 
same for all sports, with only particular exceptions (Handelsman, 2015).  While these 59 
strategies might be compelling to avoid the emphasis of anti-doping on particular sports, 60 
or athletes, this approach perhaps precludes the use of more rationalised methods to fight 61 
against doping.  It is likely that sports-specific anti-doping rules, based on the most typical 62 
doping misconduct in each sport, might be essential for developing more preventive and 63 
dissuasive anti-doping programmes.   64 
Adopting anti-doping policies that consider doping as a phenomenon strongly 65 
tailored by the characteristics of each sport might be more effective to accommodate the 66 
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differences in cheating misbehaviour among sports disciplines.  This approach should 67 
then consider what prohibited substances and methods are more commonly used or found 68 
in each sport to increase the pressure to specifically pursue them in anti-doping control 69 
testing.  One recent example is the prohibition of tramadol, adopted only by the Union 70 
Cycliste Internationale (Union Cyclste Internationale, 2019) in response to the high use 71 
of this opioid mainly in road cycling (Baltazar-Martins, Plata, et al., 2019; Baltazar‐72 
Martins et al., 2019).  Other evidence also suggests the convenience of sports-specific 73 
anti-doping protocols, such as the uneven incidence of doping across Olympic sports 74 
(Aguilar-Navarro, Muñoz-Guerra, Plata, & Del Coso, 2019), showing that doping is not 75 
a homogeneous phenomenon in sport. Interestingly, although doping misconduct has 76 
greatly evolved in recent years, the sports with the highest proportion of substances found 77 
in doping control samples have remained relatively the same since the creation of WADA 78 
(Aguilar-Navarro et al., 2019).  79 
In an attempt to perform more intelligent and effective anti-doping testing, 80 
WADA has released a technical document for sports specific analysis (TDSSA), intended 81 
to ensure a consistent minimum level of analysis of particular prohibited substances 82 
within certain sports (World Anti-Doping Agency, 2019b).  In addition, WADA has 83 
launched an International Standard in Testing and Investigation aimed to assess the risk 84 
of which prohibited substances and/or methods are most likely to be abused in particular 85 
sports (World Anti-Doping Agency, 2019a). Although this is a big step towards sports-86 
specific anti-doping testing, these document sets a minimum level of measurement for 87 
only a few substances, and it is not soundly based on scientific reports that confirm the 88 
substances more commonly found in each sport --probably because the evidence is 89 
scarce--.  In fact, the load of deciding what substances should be pursued in the 90 
distribution plans in each sport is imposed on anti-doping organizations which likely have 91 
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less resources to assess doping trends in each sport.  Thus, the aim of the current 92 
investigation was to analyse the number and distribution of adverse analytical findings 93 
per drug class in individual and team sports using data from doping control testing.   94 
 95 
Materials and Methods 96 
The present study is an analysis of the Testing Figures Reports made available 97 
annually by WADA.  These Reports include information from WADA-accredited 98 
laboratories regarding the number of samples analysed and the number of adverse 99 
findings per drug class. As per definition of the World Anti-Doping Code, and adverse 100 
analytical finding was defined as a report from a WADA-accredited laboratory or other 101 
WADA approved laboratory that identifies in a sample obtained in a doping control test 102 
the presence of a prohibited substance or its metabolites or markers.  The evidence of the 103 
use of a prohibited method was also considered as an adverse analytical finding.  104 
Although WADA has been publishing the Testing Figures Report since 2003, information 105 
about the adverse analytical findings per drug class in each sport was only included for 106 
the first time in the Report of 2014.  Thus, the information to establish the banned 107 
substances more commonly found in each sport is only available in the last four Reports 108 
(2014, 2015, 2016 and 2017) and this investigation represents an analysis from 2014 to 109 
2017.   110 
In these Reports, the adverse findings are categorised following the group of 111 
substances included in the List of Banned substances (World Anti-Doping Agency, 112 
2019c) as follows: anabolic agents, peptide hormones and growth factors, β-2 agonists, 113 
hormone and metabolic modulators, and diuretics and masking agents, prohibited at all 114 
times (i.e., in- and out-of-competition); stimulants, narcotics, cannabinoids, and 115 
6 
 
glucocorticoids, prohibited only in-competition; and β-blockers, prohibited in-116 
competition in particular sports such as shooting and skiing.   117 
The current investigation presents an ad hoc analysis of adverse analytical 118 
findings per drug class in 18 individual sports (Aquatics, Athletics, Biathlon, Boxing, 119 
Canoe/Kayaking, Cycling, Fencing, Gymnastics, Judo, Rowing, Shooting, Skating, 120 
Skiing, Taekwondo, Tennis, Triathlon, Weightlifting and Wrestling) and 7 team sports 121 
(Basketball, Football, Handball, Hockey, Ice Hockey, Rugby and Volleyball).  As it was 122 
impossible to analyse all the sports included in the WADA Testing Figures Reports, the 123 
above-mentioned individual and team sports were selected because they accounted for at 124 
least 1,400 samples per year in all the years examined.  This cut-off was selected to 125 
guarantee that the distribution of adverse findings per drug class was representative of 126 
each sport.  In addition, the use of the aggregated data of the 4 available Reports made it 127 
possible to increase the statistical power of the analysis.  Of note, only complex team 128 
sports were labelled as a “team sport”, while other individual disciplines with some 129 
collective events (such as athletics, swimming, cycling, rowing, etc) remained labelled as 130 
an “individual sport” because most of the samples analysed came from the individual 131 
events.  This analysis has followed a similar pattern to a previous publication in which 132 
the differences in the frequency of adverse analytical and atypical findings among sports 133 
was assessed (Aguilar-Navarro et al., 2019). 134 
 135 
Statistical analysis 136 
The data were electronically extracted from the Testing Figures Reports and 137 
entered into a database designed for the purposes of this research. The data were extracted 138 
by one author (MAN) using a spreadsheet (Excel 2016, Microsoft Office, WA, USA) and 139 
then they were checked for accuracy by another author (JDC).  Then, mean and standard 140 
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deviation (SD) were obtained for the number of samples analysed, the number of adverse 141 
analytical findings and the number of adverse and analytical findings per drug class from 142 
the total of the years investigated (2014-2017). Afterwards, the proportion of adverse 143 
analytical findings in each sport was calculated annually by dividing the number of 144 
adverse analytical findings by the number of samples.  The proportion of analytical 145 
findings per drug class in each sport was calculated by dividing the number of adverse 146 
findings in each drug category by the total number of adverse findings.   147 
A one-way analysis of variance was used to detect differences in the frequency of 148 
adverse findings among sports.  The Games-Howell post-hoc analysis was then employed 149 
to identify differences among sports in this variable. The differences in distribution of the 150 
adverse analytical findings per drug class were tested with crosstabs and Chi Square tests, 151 
including adjusted standardised residuals. Briefly, it was considered that a sport had a 152 
distribution of adverse findings per drug class statistically different from expected when 153 
its distribution of findings among all the drug categories was > or<the critical value of Z 154 
(i.e., 1.96).  The data were analysed with the statistical package SPSS v 20.0 (SPSS Inc., 155 
Chicago, IL). The significance level was set at p<0.05 (i.e., p<5.0 ×10-2). 156 
 157 
Results 158 
A total of 513,157 samples were analysed from the individual sports selected for 159 
this investigation from 2014 to 2017.  Table 1 contains information about the number of 160 
samples analysed per year in each sport presented as mean ± SD.  Overall, the frequency 161 
of adverse analytical findings in individual sports was 1.0 ± 0.6%, although there were 162 
substantial differences in the proportion of adverse findings among sports (Figure 1).  163 
Weightlifting, boxing and wrestling were the sports with the highest proportion of adverse 164 
analytical findings (p<5.0×10-2) with the remaining sports showing a proportion of 165 
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adverse findings lower than 2% in their samples for all the years analysed.  A detailed 166 
analysis of the number of adverse findings in each sport is included in Table 1.  However, 167 
to allow a better comparison of the banned substances more commonly found in each 168 
sport, the lower panel of Figure 1 contains the distribution of the adverse findings in each 169 
sport per drug category.  Table 3 contains information to identify if the distribution of 170 
findings per drug category in each sport was different from the “expected” distribution.  171 
The proportion of anabolic agents found in weightlifting and athletics was higher 172 
than expected (Table 3; (p<5.0×10-2). Peptide hormones and growth factors were more 173 
commonly found in cycling and athletics when compared to the distribution of the 174 
remaining sports (p=2.9×10-47). Cycling, triathlon and aquatics had a higher proportion 175 
of β2-agonists (p=3.3×10-24), while wrestling, athletics, canoe/kayaking, biathlon, and 176 
skating presented higher than expected frequencies in hormone and metabolic modulators 177 
(p=6.1×10-54). Interestingly, diuretics and masking agents were more commonly found in 178 
boxing, wrestling, taekwondo, judo, shooting, rowing and gymnastics (p=4.0×10-68). The 179 
proportion of stimulants in cycling, rowing, aquatics, tennis, and gymnastics was higher 180 
than expected from the overall distribution present in the remaining sports (p=2.3×10-37). 181 
The proportion of narcotics was higher in cycling (p=8.6×10-3), cannabinoids were 182 
abnormally present in the samples of boxers, tennis players, and fencers (p=5.2 ×10-12), 183 
glucocorticoids were higher in cycling, triathlon, and skiing and β-blockers were only 184 
found in shooting (Table 3).   185 
In team sports, the number of samples analysed was 239,367 while the number of samples 186 
analysed per year in each team sport can be found in Table 2.  The overall frequency of 187 
adverse analytical findings in team sports was of 0.8 ± 0.3%, although, as in individual 188 
disciplines, there were substantial variations in the frequency of adverse findings among 189 
team sports (Figure 2). Rugby, ice hockey and basketball are the three sports presenting 190 
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the highest proportion of adverse findings although from a statistical point of view only 191 
rugby showed a significant difference with respect to volleyball and football (p<5.0×10-192 
2). As depicted in the lower panel of Figure 2 and Table 4, the frequency of anabolic 193 
agents was higher than expected in rugby, hockey and volleyball (p=2.8×10-11). Peptide 194 
hormones and growth factors were more commonly found in rugby (p=1.4×10-1), β2-195 
agonists in ice hockey and handball (p=1.2×10-6), and stimulants in ice hockey 196 
(p=1.84×10-5). The frequency of narcotics was higher in rugby and handball (p=1.5×10-197 
4), cannabinoids in basketball (p=3.7×10-9) and glucocorticoids in football (p=8.0×10-7). 198 
 199 
Discussion 200 
Due to the paucity of data regarding the most consumed banned substances in each 201 
sports discipline, the aim of the current investigation was to analyse the number and 202 
distribution of adverse analytical findings per drug class in individual and team sports.  203 
With this goal in mind, we used the data provided by the WADA Testing Figures Reports 204 
from 2014, the moment at which, for the first time, the adverse analytical findings in each 205 
sport were categorised per drug class.  The main outcomes of this investigation reflect an 206 
uneven distribution in the percentage of adverse findings and the distribution of these 207 
findings per drug category across all sports (Figures 1 and 2).  Overall, this investigation 208 
indicates that the banned substances more commonly detected in anti-doping control tests 209 
were different depending on the sports discipline, which suggests that doping might be a 210 
phenomenon with unique characteristics in each sport.   211 
From a simplistic point of view, physical performance in most sports might be 212 
defined as the combination of four major components: skill, strength, endurance and 213 
recovery (Handelsman, 2015).  In the market, there are drugs that have the capacity of 214 
improving these four dimensions and thus, the use of banned substances in each sport 215 
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might be dictated by these dimensions of sports performance.  For instance, as proposed 216 
previously (Handelsman, 2015), sports requiring maximal force and explosive power are 217 
most susceptible to androgen doping through their effect on increasing muscle mass and 218 
strength.  Sports requiring aerobic endurance capacity are likely most susceptible to blood 219 
doping or other strategies to artificially increase the blood’s oxygen carrying capacity to 220 
exercising muscle. Contact sports and those involving intense physical activity or training 221 
may also be enhanced by growth hormone and glucocorticoids because of their effect on 222 
enhancing tissue recovery from injury.  Finally, sports that are influenced by skill and 223 
concentration may benefit from drugs that reduce anxiety, tremor, inattention or fatigue.  224 
The proposal raised by Handelsman (2015) is an interesting theorical approach to the 225 
differences in the banned substances more commonly used in each sport, and it is partially 226 
supported by the facts presented in this investigation. 227 
As previously found (Aguilar, Muñoz-Guerra, Plata, & Del Coso, 2017), anabolic 228 
agents are the most common banned substances detected when accounting for all 229 
individual and team sports, with the remaining groups of substances being found much 230 
less frequently.  However, the novelty of this investigation is that it pinpoints which sports 231 
had a higher number and proportion of adverse findings related to anabolic agents (Table 232 
1, 2, 3 and 4).  In this respect, weightlifting, canoeing, and athletics —individual sports— 233 
and rugby, hockey and volleyball —team sports— were the ones in which the percentage 234 
of anabolic agents in adverse doping control tests was higher than expected, compared to 235 
the remaining sports.  Despite the differences in the competition rules of these sports, all 236 
of them are characterised by the necessity of maximal force/power production.  In 237 
addition, in these sports, the athlete’s body mass/muscle mass/girth are not detrimental 238 
for success.  Interestingly, a high rating of adverse findings by anabolic agents is not 239 
present in other strength- and power-based sports where an increase in body mass reduces 240 
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performance (i.e., gymnastics) or implies a change of category (i.e., boxing, wrestling, 241 
taekwondo, etc).  Thus, the implementation of the steroidal module of the Athlete 242 
Biological Passport might be of little value in these particular sports.   243 
On the other hand, growth factors and peptide hormones were more commonly 244 
found in cycling, athletics, and rugby.  In the list of banned substances (World Anti-245 
Doping Agency, 2019c), the group of growth factors and peptide hormones mainly 246 
contains drugs with the potential of increasing the blood-oxygen carrying capacity, such 247 
as erythropoietins and hypoxia-inducible-factor activating agents.  Thus, it might be fairly 248 
speculated that athletes of these three sports might be more prone to using artificial 249 
manipulations of the blood, coinciding with previous data obtained by questionnaire 250 
(Alaranta et al., 2006).  This might be especially applicable to cycling and athletics 251 
because they had > 30 adverse findings per year in this category of substances (with only 252 
~2 findings per year in rugby; Table 1 and 2).  Conversely, the presence of adverse 253 
findings due to growth factors and peptide hormones in other sports such as shooting, 254 
gymnastics, fencing and most team sports was negligible which suggests that the doping 255 
controls to search for this class of drugs might be avoided in several disciplines.   256 
Cycling, triathlon and aquatics —individual sports—, and ice hockey and 257 
handball —team sports— had an unusually high proportion of β2-agonists in the doping 258 
control tests than the remaining sports.  Although β2-agonists are substances prohibited 259 
in- and out-of-competition, WADA currently allows the therapeutic use of salbutamol, 260 
formoterol and salmeterol and these substances are only considered as an adverse finding 261 
when they surpass a threshold (World Anti-Doping Agency, 2019c).  Furthermore, ~4% 262 
of athletes request a Therapeutic Use Exemption (TUE) for other β2-agonists, such as 263 
terbutaline, because they have objectively demonstrated that they suffer from asthma or 264 
exercise-induced bronchoconstriction (Anderson et al., 2006).  Thus, it is likely that the 265 
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high proportion of adverse findings due to β2-agonists in the aforementioned sports is the 266 
result of the higher number of TUEs in these particular sports.  The use of medical 267 
exemptions has raised concerns because approximately 40% of all Olympic athletes 268 
suffer from asthma in certain sports disciplines (Herzog, 2017) and it has been recently 269 
suggested that the therapeutic exemption for β2-agonists should be revisited by anti-270 
doping authorities as athletes might be using the TUEs to obtain other performance 271 
enhancing-properties of these drugs (Jacobson & Fawcett, 2016; Jacobson & Hostrup, 272 
2017).  273 
Higenamine is a β2-agonist commonly found in dietary supplements, particularly 274 
in those with purported effects associated to enhanced performance and body weight loss.  275 
From 2016, the urine samples containing higenamine were considered as an adverse 276 
analytical finding and some athletes have claimed since then that they were inadvertently 277 
consuming this substance through adulterated dietary supplements (Grucza et al., 2019).  278 
In fact, studies of dietary supplements conducted by the Netherlands Food and Consumer 279 
Product Safety Authority between 2013 and 2018 found that ~10% of dietary supplements 280 
under analysis were adulterated with higenamine (Biesterbos, Sijm, van Dam, & Mol, 281 
2019).  Thus, the unusually high proportion of β2-agonists in the doping control tests 282 
cycling, triathlon and aquatics might be associated to the use of supplements adulterated 283 
with higenamine, because these three sports are within the sports with the highest 284 
prevalence of dietary supplements use (Baltazar-Martins, Brito de Souza, et al., 2019).   285 
Another interesting outcome of this investigation is the high rating of diuretics 286 
and masking agents found in sports such as boxing, wrestling, taekwondo and judo.  287 
Fasting, skipping meals, and exercise-induced dehydration protocols are common and 288 
legal methods of rapid weight loss used prior to competition in weight category sports.  289 
However, around 20% of weight-category athletes also indicate the use of diuretics or 290 
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other pharmacological methods for reducing weight (Berkovich, Stark, Eliakim, Nemet, 291 
& Sinai, 2019).  Although gymnastics is not a weight-category discipline, a low body 292 
mass and other anthropometric factors related to thinness might be perceived as helpful 293 
for performance and the current data indicate that the control of diuretics should also be 294 
focused on gymnasts.  Of note, a high proportion of diuretics was also found in shooting, 295 
despite diuretics or other similar agents not having a clear advantage for accuracy during 296 
shots.  Perhaps, diuretics might be employed to mask the use of beta-blockers in shooting 297 
(Figure 1), which has been shown in this sport (Fitch, 2012).  In any case, the search for 298 
diuretics and masking agents in doping control testing should be kept in all disciplines as 299 
a low but stable level of this group of substances is found across all sports. 300 
Overall, stimulants were the most prevalent group of substances found in the 301 
doping control tests within the group of banned substances that are prohibited only in-302 
competition (Aguilar et al., 2017).  Despite the ease with which they can be detected in 303 
the laboratory, and the proven effectiveness to increase performance of other legal 304 
stimulants such as caffeine (Aguilar-Navarro et al., 2019; Salinero, Lara, & Del Coso, 305 
2019), the current analysis indicates that banned stimulants are still popular among 306 
athletes (Deventer, Roels, Delbeke, & Van Eenoo, 2011).  Perhaps, the high frequency of 307 
supplements contaminated with prohibited stimulants such as oxilofrine and 308 
methylhexanamine (Mathews, 2018) affects the elevated number of adverse analytical 309 
findings associated to these group of substances.  Particularly, the proportion of adverse 310 
findings due to stimulants was abnormally high in cycling, rowing, aquatics, tennis, and 311 
ice hockey.  To our knowledge, there is no a clear explanation for the high use of 312 
stimulants in most of these disciplines -when compared to the remaining disciplines- and 313 
this might be an artefact of the statistical comparison rather than a sign of abuse in these 314 
sports.  However, the motives for the high proportion of stimulants in gymnastics should 315 
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be further investigated because ~56% of the total number of adverse finding in gymnasts 316 
was related to the use of a banned stimulant. Interestingly, stimulants are typically used 317 
as treatment for attention-deficit/hyperactivity disorder (ADHD) among elite athletes, 318 
which has raised concerns in last years. To this regard, it has been argued that stimulant 319 
use may be a reasonable option for school-age athletes with ADHD but no at the 320 
professional level (Reardon & Factor, 2016) while others state that banning therapeutic 321 
use of stimulants may lead to an unfair playing field for athletes with ADHD (Garner, 322 
Hansen, Baxley, & Ross, 2018). Gymnastics have a high proportion of young athletes it 323 
might be speculated that the high use of stimulants in this sport might be in part the result 324 
of the use of this type of drug as a treatment for ADHD.  However, this speculation merits 325 
further investigation.  326 
The use of cannabinoids was higher than expected in boxers, fencers and 327 
basketball and tennis players.  Because there is no evidence to support the ergogenic 328 
effect of cannabinoids in sport (Kennedy, 2017), it is presumable that the high rating of 329 
cannabinoids in doping control testing of these sports is due to its popularity as a social 330 
drug.  In any case, the lack of performance effect does not dispute the necessity of 331 
prohibiting cannabinoids in these and other sports due to the proven adverse effect that 332 
these drugs have on athletes (Saugy et al., 2006).  Lastly, a higher effort for controlling 333 
the use of glucocorticoids might be recommended in cycling, skiing and football, because 334 
they presented an atypically high proportion of adverse findings in these sports.  Although 335 
the use of glucocorticoids is in most cases to treat sports-specific injuries in these 336 
disciplines (Dvorak, Feddermann, & Grimm, 2006; Earl et al., 2014) the monitoring of 337 
this group of substances in out-of-competition samples might help to ascertain whether 338 
some athletes use them as a doping agent to increase several aspects of sports performance 339 
(Heuberger & Cohen, 2019).   340 
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Within the group of hormone and metabolic modulators, it is worth mentioning 341 
the case of meldonium, an anti-ischaemic drug that some athletes seemed to be under the 342 
wrong impression that was a stealth drug, that evaded detection.  Meldonium was 343 
primarily manufactured by a Latvian drug company and the drug was registered for use 344 
throughout Eastern Europe countries.  Although the scientific evidence of the 345 
performance enhancing properties of meldonium was scarce (Schobersberger, Dünnwald, 346 
Gmeiner, & Blank, 2017), in January 2016, WADA decided to include meldonium in the 347 
list of banned drugs because evidence of the abuse of this substance by athletes with 348 
intentions of increasing performance (World Anti-Doping Agency, 2016).  After the 349 
inclusion of meldonium in the list of banned substances, numerous athletes were tested 350 
positive for this drug in 2016 (515 cases) and 2017 (79 cases).  In our analysis, wrestling, 351 
athletics, canoe/kayaking, biathlon, and skating presented higher than expected 352 
frequencies in hormone and metabolic modulators.  The Report WADA Report of adverse 353 
analytical findings does not offer information of the substances detected in each sport and 354 
we cannot certify that these sports presented more cases of meldonium in 2016 and 2017.  355 
However, it is highly likely that the abnormal frequency of hormone and metabolic 356 
modulators in these sports was somewhat related to the inclusion of meldonium in the 357 
prohibited list, particularly because meldonium represented 71% of all the adverse 358 
findings related to hormone and metabolic modulators in 2016.   359 
The current investigation presents some limitations that should be discussed to 360 
correctly understand the outcomes of the research.  First, this investigation only contains 361 
information about prohibited substances, but it lacks data on the prevalence of prohibited 362 
methods employed to increase performance, such as manipulation of blood and blood 363 
components, and chemical and physical manipulations.  Further investigations should 364 
explore whether the use of prohibited methods is also affected by the characteristic of the 365 
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sport.  Secondly, the current investigation analyses the number of samples and adverse 366 
findings reported by WADA-accredited laboratories.  However, not all the adverse 367 
findings finish in an adjudicated or sanctioned anti-doping rule violation (de Hon & van 368 
Bottenburg, 2017).  This is because all adverse findings are subjected to a results 369 
management process which includes matching results with TUEs and/or longitudinal 370 
studies, which can result in no sanction.  In addition, sports tribunals that evaluate doping 371 
cases occasionally determine that the athletes are not at fault even after a clear adverse 372 
finding has been reported by a WADA-accredited laboratory.  Thus, the outcomes of this 373 
investigation cannot be extrapolated to infer the proportion of sanctioned doping 374 
misconducts in each sport.  Finally, the analysis presented here included information of 375 
only 4 reports (from 2014 to 2017) and further reports should be used to strengthen the 376 
outcomes of this investigation.  377 
In conclusion, the analysis of the WADA Testing Figures Reports suggests that 378 
the prohibited substances used as doping agents might be substantially different 379 
depending on the type of sport. Thus, the outcomes of this research indicate that more 380 
sports-specific anti-doping strategies should be implemented to enhance the efficacy of 381 
the current anti-doping testing protocols, following the lead already initiated with the 382 
International Standard for Testing and Investigation and the TDSSA (World Anti-Doping 383 
Agency, 2019b).  Specifically, the pressure to search for anabolic agents should be 384 
increased in sports where maximal muscle strength and power are imperative for success, 385 
but in which increased body mass and muscle mass have not a negative impact on 386 
performance.  Peptide hormones and growth factors should be mostly looked for in 387 
samples from endurance disciplines such as cycling and athletics, while the search for 388 
these substances might not need to be arranged in other sports such as shooting, 389 
gymnastics and fencing.  The concession of TUEs for β2-agonists should be further 390 
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studied in sports such as cycling, triathlon and aquatics because an atypically high 391 
proportion of β2-agonists are found in these samples.  A higher anti-doping pressure in 392 
controlling the use of diuretics should be made in weight-category sports, especially on 393 
the days preceding the weigh-in for competition.  The percentage of stimulants in adverse 394 
findings was moderate-to-high in most sports disciplines and thus, anti-doping control 395 
testing for this group of banned substances should be transversal in all sports; however, 396 
special attention to control the use of stimulants should be imposed in gymnastics.  397 
Finally, greater scientific attention to ascertain the motives for using glucocorticoids 398 
should be paid in cycling, skiing and football.  These sports-specific anti-doping policies 399 
might be helpful to enhance the efficacy of the anti-doping testing and make elite sport 400 
fairer.   401 
  402 
  403 
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Table 1.  Number of samples and number of adverse analytical findings in individual sports according to the categories of banned substances 










Hormones Diuretics Stimulants Narcotics Cannabinoids Glucocorticoids 
Weightlifting 9618±930 163.0±67.3 4.3±2.9 4.3±3.5 19.8±14.9 21.5±9.0 20.3±3.8 0.8±0.9 1.8±0.5 4.8±2.2 
Boxing 4476±392 30.8±9.5 0.8±0.5 5.0±1.2 10.0±9.9 24.0±5.2 12.8±4.2 1.0±1.4 5.0±2.9 3.3±2.9 
Wrestling 5121±209 43.3±10.5 1.3±0.9 2.0±1.6 21.3±31.6 18.0±2.2 10.0±5.4 0.3±0.5 2.5±2.4 2.3±2.2 
Cycling 22958±497 95.3±9.9 43.5±5.3 20.8±2.5 16.0±14.6 16.8±5.1 59.5±5.7 6.5±5.4 2.31±0.9 56.8±14.2 
Taekwondo 1980±195 8.5±2.4 0.5±0.8 0.8±0.9 2.0±3.4 8.3±2.8 1.5±0.6 0.3±0.5 0.7±0.6 0.8±0.5 
Judo 4449±480 17.5±7.8 0.3±0.5 1.8±1.5 6.3±6.7 13.0±3.6 8.5±3.9 0.3±0.5 1.5±1.7 2.0±2.2 
Athletics 29764±2678 148.8±6.7 30.8±8.2 13.3±3.2 48.5±60.8 24.3±6.1 39.3±7.0 2.0±1.1 3.0±2.8 31.3±3.6 
Canoe/kayaking 4293±278 17.8±2.5 1.3±0.9 1.0±0.0 14.8±22.9 1.2±0.5 3.8±2.2 0.5±0.6 1.5±0.7 1.5±1.2 
Shooting 2204±627 2.3±2.1 0.0±0.0 0.8±0.9 1.0±0.8 5.0±2.6 2.8±1.5 0.3±0.5 0.5±0.6 0.0±0.0 
Triathlon 3946±324 5.5±2.1 1.5±1.7 5.8±2.8 3.0±3.0 2.5±1.3 5.5±1.9 0.3±0.5 0.0±0.0 4.8±0.5 
Rowing 4834±369 10.5±4.0 0.3±0.5 2.3±1.5 4.3±5.3 7.8±3.5 8.5±4.2 0.0±0.0 0.0±0.0 1.0±0.8 
Aquatics 13851±1546 25.8±9.7 1.8±2.2 11±5.5 11.3±17.3 9.5±4.8 20.5±6 0.3±0.5 2.3±2.1 7.0±2.2 
Tennis 4699±896 7.5±7.7 0.8±0.9 0.3±0.5 3.3±3.8 2.3±1.9 8.8±6.3 0.3±0.5 1.5±1.3 2.8±0.9 
Gymnastics 2270±138 0.8±0.5 0.0±0.0 0.3±0.5 0.7±1.2 4.5±2.9 8.3±3.9 0.0±0.0 0.3±0.6 0.3±0.5 
Biathlon 2062±313 1.5±1.9 0.5±1.0 0.0±0.0 5.6±7.4 0.8±0.9 0.3±0.6 0.0±0.0 0.0±0.0 1.0±1.4 
Fencing 1644±123 1.8±1.5 0.0±0.0 0.8±0.9 0.0±0.0 1.3±0.9 0.8±0.9 0.0±0.0 0.8±0.5 1.3±0.9 
Skating 4168±719 2.5±1.3 0.3±0.5 1.0±2.0 5.8±10.2 0.8±0.9 2.8±1.5 0.0±0.0 0.3±0.5 0.8±0.9 
















Hormones Diuretics Stimulants Narcotics Cannabinoids Glucocorticoids 
Rugby 7602±629 45.5±5.9 1.8±1.7 6.0±2.8 6.3±5.3 4.5±1.7 15.5±6.5 4.3±5.2 5.8±4.4 7.3±2.1 
Ice hockey 3579±349 4.8±4.9 0.0±0.0 5.0±3.6 3.3±4.9 1.0±1.2 11.8±8.5 0.3±0.5 4.7±2.5 2.3±1.7 
Basketball 5429±258 14.8±10.8 0.0±0.0 3.0±2.4 3.0±0.8 2.8±2.2 15.8±1.7 0.3±0.5 11.3±4.1 4.0±0.8 
Handball 3790±223 8.0±4.9 0.0±0.0 4.3±3.2 1.3±1.5 1.3±0.5 6.5±3.4 1.5±1.7 2-0±0.8 0.8±1.5 
Hockey 1550±112 5.0±3.2 0.0±0.0 0.3±0.5 0.8±0.5 0.5±0.6 1.5±1.3 0.0±0.0 1.3±0.6 0.8±0.5 
Volleyball 4404±151 12.0±6.7 0.0±0.0 1.3±1.5 1.7±2.8 2.3±0.9 5.5±2.5 0.0±0.0 2.0±1.4 1.5±1.0 











Table 3.  Between-sport comparison distribution of adverse analytical findings in individual sports according to the categories of banned substances 


















Stimulants Narcotics Cannabinoids Glucocorticoids β-blockers 
Weightlifting  + - - - - - - - - - 
Boxing  - - • • + • • + - - 
Wrestling  • - - + + - • • - - 
Cycling  - + + - - + + - + - 
Taekwondo  • • • • + - • • • - 
Judo  • - • • + • • • - - 
Athletics  + + - + - - • - • - 
Canoe/kayaking  + • • + - - • • - - 
Shooting  - • • • + • • • - + 
Triathlon  - • + • • • • • + - 
Rowing  - - • • • + • • - - 
Aquatics  - - + • • + • • • - 
Tennis  - • • • • + • + • - 
Gymnastics  - • • - + + • • • - 
Biathlon  - • • + • • • • • - 
Fencing  • • • • • • • + • - 
Skating  - • • + • • • • • - 
Skiing  - • • • • • • • + - 
 
(+) Depicts that the proportion of adverse analytical findings for this category was higher than expected at (p<5.0×10-2). 
(-) Depicts that the proportion of adverse analytical findings for this category was lower than expected at (p<5.0×10-2). 




Table 4.  Differences in distribution of adverse analytical findings in team sports according to the categories of banned substances proposed by 
WADA. 









Stimulants Narcotics Cannabinoids Glucocorticoids 
Rugby  + + • • • - + - - 
Ice hockey  - • + • • + • • • 
Basketball  - • • • • • • + • 
Handball  • • + • • • + • - 
Hockey  + • • • • • • • • 
Volleyball  + • • • • • • • • 
Football  • • - - • • • • + 
 
(+) Depicts that the proportion of adverse analytical findings for this category was higher than expected at (p<5.0×10-2). 
(-) Depicts that the proportion of adverse analytical findings for this category was lower than expected at (p<5.0×10-2). 




Figure 1. (A) Percentage of adverse analytical findings and (B) distribution of adverse 
analytical findings per category of banned substances in individual sports.  The data are 
mean ± SD for each sport between 2014 to 2017.  
 
 
WEI = Weightlifting; BOX = Boxing; WRE = Wrestling; CYC = Cycling; TAE = 
Taekwondo; JUD = Judo; ATH= Athletics; CAN = Canoe/Kayaking; SHO = Shooting; 
TRI = Triathlon; ROW = Rowing; AQU = Aquatics; TEN = Tennis; GYM = Gymnastics; 
BIA = Biathlon; FEN = Fencing; SKA = Skating; SKI = Skiing.  The category of “beta-
blockers” has been included in this graph although this group of substances is only banned 
in shooting and in some specialities of skiing.   
 
(*) Different from WEI at (p<5.0×10-2); (†) Different from BOX at (p<5.0×10-2); (‡) 

































































Figure 2. (A) Percentage of adverse analytical findings and (B) distribution of adverse 
analytical findings per category of banned substances in team sports.  The data are mean 
± SD for each sport between 2014 to 2017.   
 
 
RUG = Rugby; ICE = Ice Hockey; BAS = Basketball; HAN = Handball; HOC = Hockey; 
VOL = Volleyball; FOO = Football.  The category of “beta-blockers” is not included in 
this graph because this group of substances is not banned in team sports.   
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